Pharmaceutical

Subasumstat by Takeda Pharmaceutical for Relapsed Multiple Myeloma: Likelihood of Approval

Subasumstat is under clinical development by Takeda Pharmaceutical and currently in Phase II for Relapsed Multiple Myeloma.

Jan 9, 2024 - 18:00
Subasumstat by Takeda Pharmaceutical for Relapsed Multiple Myeloma: Likelihood of Approval
Subasumstat is under clinical development by Takeda Pharmaceutical and currently in Phase II for Relapsed Multiple Myeloma.
Read the original article

Tags:

Previous Article

HH-006 by Huahui Health for Hepatitis D: Likelihood of Approval

Next Article

AUR-101 by Aurigene Oncology for Psoriatic Arthritis: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Wegovy cardiovascular study has doctors seeing new possibilities in weight loss drug

STAT+: Wegovy cardiovascular study has doctors seeing n...

Aug 9, 2023

CT-080 by First Condor Group for Gastric Cancer: Likeli...

Oct 3, 2023

What’s behind the urge to scratch that itch? Harvard researchers have a theory

What’s behind the urge to scratch that itch? Harvard re...

Nov 23, 2023